We present the data from 105 patients with primary epithelial ovarian dancer, who received up to 6 cycles of carboplatin (300 mg/m(2)) and cisplatin (100 mg/m(2)) as one treatment arm of a prospective randomized trial. Values for first-course carboplatin area-under-the-curve (AUC) were determined retrospectively. WHO grade 3-4 thrombocytopenia was found in 10% of patients with low AUC (AU
One hundred sixty-four patients with stage III-IV epithelial ovarian carcinoma were randomized to re...
OBJECTIVE: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...
International audiencePurpose Area under the curve (AUC) dosing is routinely carried out for carbopl...
The efficacy and toxicity of a combination of carboplatin and cyclophosphamide (CC) were studied in ...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D...
Eleven untreated patients with advanced ovarian cancer were studied for tolerance and response to co...
To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered ...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
Background – To evaluate the feasibility, efficacy, and toxicity of the combination of carboplatin p...
This prospective multicentre phase III trial was conducted to assess whether increased platinum dose...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comp...
One hundred sixty-four patients with stage III-IV epithelial ovarian carcinoma were randomized to re...
OBJECTIVE: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...
International audiencePurpose Area under the curve (AUC) dosing is routinely carried out for carbopl...
The efficacy and toxicity of a combination of carboplatin and cyclophosphamide (CC) were studied in ...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D...
Eleven untreated patients with advanced ovarian cancer were studied for tolerance and response to co...
To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered ...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
Background – To evaluate the feasibility, efficacy, and toxicity of the combination of carboplatin p...
This prospective multicentre phase III trial was conducted to assess whether increased platinum dose...
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian ...
The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comp...
One hundred sixty-four patients with stage III-IV epithelial ovarian carcinoma were randomized to re...
OBJECTIVE: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...